Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) EBIT Margin (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of EBIT Margin data on record, last reported at 27.98% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 5650.0% year-over-year to 27.98%; the TTM value through Dec 2025 reached 10.08%, changed N/A, while the annual FY2025 figure was 5.56%, 6792.0% up from the prior year.
  • EBIT Margin reached 27.98% in Q4 2025 per CAI's latest filing, up from 241.67% in the prior quarter.
  • Across five years, EBIT Margin topped out at 490.06% in Q2 2024 and bottomed at 241.67% in Q3 2025.